相关实验视频

Updated: Aug 1, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

发展性毒性的无动物评估:结合PBPK建模与ReproTracker测定

Marjory Moreau¹, Amer Jamalpoor², John Carter Hall¹

¹ScitoVation, LLC, Research Triangle Park, NC 27713, USA.

|November 29, 2023

概括

人类干细胞测试ReproTracker现在可以定量预测发育性毒性. 将其与药理动力学建模相结合,可以提供安全,无动物药物和化学品风险评估.

科学领域:

毒理学毒理学毒理学
药理动力学药理动力学
干细胞生物学干细胞生物学

背景情况:

在体外查测试平台的产性正在进步.
基于人体诱导多能干细胞 (hiPSCs) 的测定方法ReproTracker可靠地识别出潜在的病原体.
目前的限制包括量化临床剂量与发育毒性的相关性.

研究的目的:

为了评估ReproTracker是否可以在体内外推.
量化预测thalidomide和carbamazepine的发育性毒性暴露水平.
整合生理学基础的药理动力学 (PBPK) 建模与体外数据.

主要方法:

使用PBPK建模来描述化合物的药理动力学.
采用了体外到体外抽取方法 (IVIVE) 的方法.
从ReproTracker度中预测的人类等效剂量 (HED).

主要成果:

从ReproTracker获得的HED与已报告的人类致剂量非常相匹配.
预测的HED与大鼠和子发育毒性研究的发现保持一致.
从ReproTracker衍生出的HED显示出灵敏度和人类保护能力.

结论:

整合PBPK建模对于抽出体外发育毒性数据至关重要.
结合ReproTracker和PBPK建模,可以提高药物和化学品安全性评估.
这种方法为开发性毒性评估提供了对动物试验的潜在替代方案.

关键词:

发展性毒性发展性毒性人类诱导的多能干细胞干细胞.在体外到体内抽象的抽象.新方法方法论新方法方法论在 PBPK 建模中使用 PBPK 模型.在 ReproTracker 上使用 ReproTracker.

更多相关视频

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos

Published on: August 25, 2019

Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae

Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae

Published on: March 7, 2025

相关概念视频

Toxicity Testing in Animals

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...